CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.23% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.06M.
Overvalued
The company’s latest PE is -2.07, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.20M shares, decreasing 5.98% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.40K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.03.